

In re Application of: Ashok AMIN, et al.

Serial No.: 09/925,970

Filed: August 10, 2001

For: METHOD FOR TREATING HEPATITIS

Art Unit: 1648

Confirmation No.: 4363

Examiner: D.C. WORTMAN

Washington, D.C.

Atty.'s Docket: AMIN 4A

Date: June 25, 2002

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment []

in the above-identified application.

[XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

[] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

[] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	Small Entity	Other Than a Small Entity
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Rate	Additional Fee
Total	6	Minus	20	0
Indep.	1	-Minus	3	0
First Presentation of Multiple Dependent Claim			140	\$
TOTAL ADDITIONAL CLAIMS FEE			\$	Total

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[XX] First - \$ 55.00

[] Second - \$200.00

[] Third - \$460.00

[] Fourth - \$720.00

Other Than Small Entity

Response Filed Within

[] First - \$ 110.00

[] Second - \$ 400.00

[] Third - \$ 920.00

[] Fourth - \$1440.00

[], Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ is attached (check no.).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 55.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
Attorneys for Applicant(s)

Facsimile: (202) 737-3528

Telephone: (202) 628-5197

By:

Anne M. Kornbau

Registration No. 25,884

AMK:nmp

G:\BN\N\nyum\Amin4a\PTO\cov1.wpd



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: AMIN 4A

Application of:

Ashok AMIN, et al.

Serial No.: 09/925,970

Filed: August 10, 2001

For: METHOD FOR TREATING
HEPATITIS

) Art Unit: 1648
)
) Examiner: D.C. WORTMAN
)
) Confirmation No. 4363
)
) Washington D.C.
)
) June 25, 2002
)

TECH CENTER #600/2900

JUL 18 2002

RECEIVED

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of
February 25, 2002, for which a one month extension of
time to respond is hereby requested, please enter the
following amendment:

IN THE SPECIFICATION

Page 2, please amend paragraph [0006] as
follows:

[0006] There are currently two drugs which
have been approved for treatment of rheumatoid arthritis
that act by neutralizing the activity of secreted TNF:
etanercept (ENBREL), which is based on a p75:pC receptor
and a humanized monoclonal antibody that neutralizes the
activity of TNF, such as ~~in~~flixamab (REMICADE).
Etanercept, or ENBREL, is an extracellular ligand binding
protein of the human p75 TNF receptor (TNF-R) linked to